These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 33745079)

  • 21. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
    Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
    Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 27. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
    Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
    Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
    Kudo M; Tsuchiya K; Kato N; Hagihara A; Numata K; Aikata H; Inaba Y; Kondo S; Motomura K; Furuse J; Ikeda M; Morimoto M; Achira M; Kuroda S; Kimura A
    J Gastroenterol; 2021 Feb; 56(2):181-190. PubMed ID: 33392749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
    Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
    Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment.
    Chan SL; Ryoo BY; Mo F; Chan LL; Cheon J; Li L; Wong KH; Yim N; Kim H; Yoo C
    J Hepatol; 2024 Aug; 81(2):258-264. PubMed ID: 38570034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
    Nguyen L; Chapel S; Tran BD; Lacy S
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):577-589. PubMed ID: 31637577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
    N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
    Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
    Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
    Personeni N; Pressiani T; Rimassa L
    Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
    Rimini M; Yoo C; Lonardi S; Masi G; Granito A; Bang Y; Rizzato MD; Vivaldi C; Ielasi L; Kim HD; Bergamo F; Salani F; Leoni S; Ryoo BY; Ryoo MH; Burgio V; Cascinu S; Casadei-Gardini A
    Target Oncol; 2021 Sep; 16(5):653-661. PubMed ID: 34491510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib: a promising treatment for hepatocellular carcinoma.
    Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
    Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.